GlobeImmune Inc. announced that updated results from eleven chordoma patients in the GI-6301 Phase 1 trial were presented at the 2014 CTOS Annual Meeting in Berlin, Germany. Christopher R. Heery, M.D., Head, Clinical Trials Group, Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI) presented the data during his talk entitled "NCI Experience Using Yeast-Brachyury Vaccine (GI-6301) in Patients with Advanced Chordoma (Paper 030)". The GI-6301 Tarmogen(R) product candidate targets cancers containing the brachyury protein.

The NCI is conducting a Phase 1 safety, immunology and early efficacy trial of GI-6301 monotherapy in patients with late-stage cancers known to express the brachyury protein including chordoma. This presentation updates data GlobeImmune previously reported on seven chordoma patients in the trial. Results to date from the eleven chordoma patients in this trial include: GI-6301 has been generally well tolerated, immunogenic, and has shown evidence of clinical activity in both advanced epithelial cancers and chordomas.

Summary results: One confirmed partial response by RECIST that has continued past one year. Eight patients with stable disease at day 85 restaging; Two of these patients had stable disease at study entry; Study status; Seven of 11 chordoma patients have left the study due to disease progression; Four of 11 chordoma patients remain on treatment with stable disease; Three of these four patients had progressive disease at study entry; 62% of all patients (all tumor types) evaluated to date in this Phase 1 trial had post-administration brachyury-specific T cell immune responses; The most common adverse events seen in this trial were mild/moderate injection site reactions.